L-030

Lurasidone hydrochloride solution

1.0 mg/mL in methanol (as free base), ampule of 1 mL, certified reference material, Cerilliant^®

• 実験式（ヒル表記法）: C₂₈H₃₆N₄O₂S · HCl
• CAS番号: 367514-88-3
• 分子量: 529.14
• EC Number: 200-659-6
• MDL番号: MFCD18917095
• UNSPSCコード: 41116107
• PubChem Substance ID: 329817348
• NACRES: NA.24

特性

• グレード: certified reference material
• 品質水準: 300
• 形状: liquid
• 特徴: Snap-N-Spike^®/Snap-N-Shoot^®
• 包装: ampule of 1 mL
• メーカー／製品名: Cerilliant^®
• 濃度: 1.0 mg/mL in methanol (as free base)
• テクニック: gas chromatography (GC): suitable; liquid chromatography (LC): suitable
• アプリケーション: clinical testing
• フォーマット: single component solution
• 保管温度: −20°C
• SMILES記法: Cl.O=C1[C@@H]2[C@H]3CC[C@H](C3)[C@@H]2C(=O)N1C[C@@H]4CCCC[C@H]4CN5CCN(CC5)c6nsc7ccccc67
• InChI: 1S/C28H36N4O2S.ClH/c33-27-24-18-9-10-19(15-18)25(24)28(34)32(27)17-21-6-2-1-5-20(21)16-30-11-13-31(14-12-30)26-22-7-3-4-8-23(22)35-29-26;/h3-4,7-8,18-21,24-25H,1-2,5-6,9-17H2;1H/t18-,19+,20-,21-,24+,25-;/m0./s1
• InChI Key: NEKCRUIRPWNMLK-SCIYSFAVSA-N
• 遺伝子情報: human ... DRD2(1813) , HTR2A(3356)

詳細

詳細

A certified solution standard suitable for use in LC/MS or GC/MS applications for clinical toxicology, forensic analysis, pharmaceutical research, or urine drug testing. Marketed under the trade name Latuda^®, lurasidone is a new atypical antipsychotic developed for the treatment of schizophrenia.

アプリケーション

• LurasiDonein Bipolar Depression Research: A study explored the pharmacodynamic properties of lurasidone, hypothesizing its efficacy in acute bipolar depression. This research provides a deep dive into the mechanistic actions of lurasidone, enhancing understanding in neuropharmacological studies and aiding in the development of more effective treatments for bipolar disorder (Fountoulakis et al., 2024).


• Quantification of LurasiDonein Clinical Samples: Development and validation of a liquid chromatography-tandem mass spectrometry method for quantifying lurasiDonein dried blood spot samples was reported. This method facilitates easier and less invasive monitoring of lurasiDonelevels in patients, crucial for effective pharmacological research and ensuring therapeutic efficacy in treatment regimes (Rajadhyaksha and Londhe, 2023).


• Novel Methodologies in Clinical Trials: Research introduced a novel method for deriving adverse event prevalence in randomized controlled trials, which could potentially improve the understanding of the benefit-risk ratio of drugs including lurasidone. This approach is particularly relevant for drug labels and regulatory submissions, ensuring safer and more effective clinical outcomes (Piacentino et al., 2024).


• Pharmacological Properties of Lurasidone: A study investigated how lurasiDoneblocks the voltage-gated potassium channels of coronary arterial smooth muscle cells, offering insights into its broader pharmacological impacts. This research is vital for assessing potential cardiovascular side effects and optimizing dosing strategies to mitigate risks in patients treated with lurasiDone(Zhuang et al., 2023).

法的情報

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany

Latuda is a registered trademark of Dainippon Sumitomo Pharma Co., Ltd.

Snap-N-Shoot is a registered trademark of Cerilliant Corporation

Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

安全性情報

• ピクトグラム: GHS02,GHS06,GHS08
• シグナルワード: Danger
• 危険有害性情報: H225,H301 + H311 + H331,H370
• 注意書き: P210 - P280 - P301 + P310 + P330 - P302 + P352 + P312 - P304 + P340 + P311
• 危険有害性の分類: Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1
• ターゲットの組織: Eyes
• 保管分類コード: 3 - Flammable liquids
• WGK: WGK 1
• 引火点(°F): 49.5 °F - closed cup
• 引火点(℃): 9.7 °C - closed cup